Vasoactive Intestinal Peptide (VIP)

ExperimentalEndogenous Neuropeptide / ResearchExperimental

VIP is an endogenous 28 amino acid neuropeptide that activates VPAC receptors to increase cAMP, driving vasodilation, bronchodilation, smooth muscle relaxation, and immunomodulatory signaling in experimental models.

Calculate Dose

For research use only.

Key Facts

CAS: 37221-79-7
Molecular Weight (MW): 3325.8 g/mol
Half-life: Not established (rapid enzymatic degradation; route dependent)
Unit: mg
Administration Route: Subcutaneous, Intramuscular, Intravenous, or Intranasal (investigational contexts)
Frequency: Not established
Last updated: 3/3/2026
Targets: VPAC1 receptorVPAC2 receptor

Overview

Protocol

Dosage Range: Not established (research only)
Frequency: Not established
Cycle: Not established (research only; do not self-administer)
Administration Route: Subcutaneous, Intramuscular, Intravenous, or Intranasal (investigational contexts)
Reconstitution Guide: Reconstitute per lab SOP (commonly bacteriostatic water) and handle cold chain as required

Science

Mechanism of Action

VIP activates VPAC receptors to increase intracellular cAMP, leading to smooth muscle relaxation, vasodilation, bronchodilation, and immunomodulatory signaling in experimental systems.

Targets

VPAC1 receptorVPAC2 receptor

Studies

— Journal/year not available
— Journal/year not available
— Journal/year not available

Benefits

Vasodilation and smooth muscle relaxation research toolBronchodilation signaling researchNeuroimmune modulation researchGI secretion and motility pathway research

Potential Side Effects

Not established in controlled human use for this product context
Class associated effects may include flushing, headache, transient hypotension, tachycardia, and GI effects depending on exposure